Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 1
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 0
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 0
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 0
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 0